	Los Gastos De Explotación		Fecha
Abbott	USD 9.21B	17M	2025-12
Acadia Pharmaceuticals	USD 266.6M	23.72M	2025-12
Agios Pharmaceuticals	USD 141.54M	11.8M	2025-12
Akebia Therapeutics	USD 43.82M	16.98M	2025-03
Alnylam Pharmaceuticals	USD 965.32M	84.27M	2025-12
AstraZeneca	USD 12.53B	4.16B	2025-12
BioMarin Pharmaceutical	USD 676.18M	131.65M	2025-12
Coherus Biosciences	USD 53.03M	43.41M	2025-03
Eli Lilly	USD 10.31B	1.09B	2025-12
Esperion Therapeutics	USD 67.66M	3.6M	2024-09
Halozyme Therapeutics	USD 211.07M	74.73M	2025-12
Illumina	USD 903M	69M	2025-12
Insmed	USD 513.55M	109.86M	2025-12
Ironwood Pharmaceuticals	USD 57.33M	8.63M	2024-12
J&J	USD 18.97B	2.38B	2025-12
Lexicon Pharmaceuticals	USD 57M	10.54M	2024-06
MacroGenics	USD 67M	8M	2025-09
MannKind	USD 119.64M	56.29M	2025-12
Merck	USD 10.16B	558M	2025-12
Moderna	USD 1.54B	259M	2025-12
Novartis	USD 9.86B	115M	2025-09
PTC Therapeutics	USD 246.3M	38.78M	2025-12
Puma Biotechnology	USD 49.26M	3.2M	2024-06
Sarepta Therapeutics	USD 853.02M	390.78M	2025-12
Thermo Fisher Scientific	USD 9.91B	867M	2025-12
Ultragenyx Pharmaceutical	USD 321M	9.82M	2025-12
United Therapeutics	USD 804.8M	5.79B	2025-12
Vanda Pharmaceuticals	USD 466M	20.33M	2025-09

Lexicon Pharmaceuticals Los Gastos De Explotación - Los valores actuales, los datos históricos, las previsiones, estadísticas, gráficas y calendario económico - Mar 2026.